Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...
Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT). These new ...
Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...
Large, prospective cohorts are needed to research the gut microbiome’s role in colorectal cancer (CRC) risk. We evaluated the gut microbiome leveraging residual fecal immunochemical tests (FIT) from a ...
Fecal immunochemical test (FIT)-based screening has been recommended as an option for population colorectal cancer (CRC) screening. However, the studies on factors associated with false-positive FIT ...
FIT outperformed cfDNA in detecting advanced precancerous colorectal lesions, showing higher sensitivity and specificity. Blood-based tests offer easier implementation and potentially higher adherence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results